For nearly 50 years, Digestive Disease Week (DDW) has been at the forefront of education and knowledge-sharing in the fields of gastroenterology, hepatology, GI endoscopy, gastrointestinal surgery and other related fields.
In 2018, over 14,000 people attended DDW in Washington DC, USA. With over 5,000 lectures, posters and abstract presentations, a wealth of data and insights were shared over the four days. With a focus on IBD, we have reviewed the abstracts, distilled the most pertinent points and developed a series of five articles that cover some of the broad themes addressed by speakers at the Congress. The current articles address new insights and recommendations for the clinical management of IBD, improving IBD outcomes through better monitoring, advances in IBD therapy, and comorbidities with additional articles being released weekly covering topics such as the use of biosimilars in IBD.
Be sure to come back next week to read the latest article and why not check out the insights shared at this year’s European Crohn’s and Colitis Organisation (ECCO) Annual Congress.
With an increasing number of biosimilars receiving approval both in Europe and the USA, should they play an increasing role in the management of IBD? In this article, we review some of the biosimilar highlights from DDW including data from the extension phase of the NOR-SWITCH trial.
With the number of treatments available for the management of IBD continuing to grow, this article covers the latest information on newly approved therapies as well as providing insights into some of the possible treatments of the future.
Should you use a treat-to-target approach for the management of IBD and what treatments should you use? This and other topics such as how and when should biologic treatments be discontinued are addressed in this article.
Alternatively login via
Back to epgonline.org